Full-Time

Scientist – Protein Biochemistry

Protein Folding/Misfolding

Posted on 8/1/2024

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology

Compensation Overview

$130k - $165kAnnually

+ Performance Bonus + Equity + Health Benefits

Mid, Senior

Palo Alto, CA, USA

Hybrid environment on the Stanford Life Sciences campus.

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • D., MD, or Ph.D./MD degree and expertise in the field of **protein folding/misfolding** (e.g., biochemistry, biophysics, molecular biology, chemical biology, chemistry, structural biology). Prior industry experience or post-doctoral training is desirable but not required
  • Demonstrated record of achievement with at least one first-author publication in the field of protein folding/misfolding or chaperones is required
  • Experience and familiarity with techniques used for studying protein folding/misfolding, such as protein expression, purification, folding kinetics/pathway investigation, folding intermediate characterization, pulse proteolysis, protein thermal stability, urea denaturation, etc., is desirable
  • Experience with a wide range of biophysical (mass spectrometry (MS), surface plasmon resonance (SPR), microscale thermophoresis (MST), isothermal titration calorimetry (ITS), protein thermal shift (PTS), dynamic light scattering (DLS)) and plate-based biochemical (FRET, MSD, ELISA) techniques
  • Experience with multichannel pipettes and semi-automatic pipetting station is a plus
  • Experience with diseases related to protein folding/misfolding and pharmacological chaperones is a strong plus
  • Strong knowledge of chemistry concepts and structure biology, including an understanding of structure-activity relationships (SAR) and structure-based drug design.
Responsibilities
  • Use a variety of biochemical, biophysical, and pharmacological techniques to advance multiple small molecule drug candidates from discovery research to clinical development
  • Develop, optimize, troubleshoot, and execute novel biochemical and cellular assays to drive preclinical drug discovery
  • Interact with our medicinal chemists to support structural activity relationship learning
  • Drive basic research towards the clinic at hyperspeed
  • Independently design, execute, and analyze experiments within our top-notch laboratory
  • Communicate findings and implications to senior leadership

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific therapies while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. With over 15 drug programs aimed at 20 different genetic diseases, BridgeBio aims to bring treatments to market more quickly than traditional biopharma processes. The company promotes a culture of independent thinking and transparency, which supports rapid, data-driven decision-making.

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

3%

1 year growth

2%

2 year growth

-2%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investment by Norges Bank shows strong investor confidence in BridgeBio.
  • Partnership with PANTHERx Rare enhances market penetration for rare disease therapies.
  • KRAS inhibitors development positions BridgeBio in a promising cancer treatment market.

What critics are saying

  • Alnylam's RNAi therapy poses competitive pressure on BridgeBio's Attruby.
  • Decentralized model may challenge cohesive strategic direction across programs.
  • Increased competition in KRAS inhibitors could impact BridgeBio's market share.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for efficient drug development.
  • Focus on genetic diseases allows targeting conditions with well-understood genetic causes.
  • Partnerships with specialty pharmacies enhance patient access to rare disease therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

INACTIVE